The overall prevalence of Nocturnal enuresis (bedwetting) is around 15 to 30%. It has  significant psychosocial impacts on affected pediatric population. These patients are usually treated conservatively with life style modifications and combination of anticholinergic and antipsychotic medications. Objective of our study is to evaluate the efficacy and safety of combined anticholinergic and antipsychotic therapy in children with persistent nocturnal enuresis.

This cross-sectional study was conducted from January 2024 to December 2024. A total of 100 children aged 5–15 years diagnosed with primary or secondary nocturnal enuresis were included in the study. All patients received a combination of anticholinergic therapy (oxybutynin,1 to 3 mg orally/ day) and low-dose anti psychotic therapy (clomipramine 25mg, half tab orally at night time). Patients were followed on week 3, 6 and 12 to assess the treatment outcomes in terms of frequency of dry nights per week, reduction in enuresis episodes, and adverse effects.

Among the 100 patients 55 were female and 45 were male, mean age was 9 years.  A 75% reduction in enuresis episodes was observed by the end of 12 weeks, while 50% patients were completely dry by the end of this period. Significant improvement was noted in age group more than 10 years with almost 80% patients reported complete dryness at the end of 12th week. These drugs were usually safe and no serious side effects were observed. The most common side effects included mild constipation (12%), drowsiness (8%), and transient mood changes in (3%) cases.

overall 75% reduction in enuresis episodes was observed by the end of 12 weeks, while 50% patients were completely dry by the end of this period. Significant improvement was noted in age group more than 10 years with almost 80% patients reported complete dryness at the end of 12th week. These drugs were usually safe and no serious side effects were observed. The most common side effects included mild constipation (12%), drowsiness (8%), and transient mood changes in (3%) cases.

Combination therapy with anticholinergic and antipsychotic medications is highly effective in reducing the frequency of nocturnal in pediatric patients. These drugs are also safe and cost effective. Further randomized controlled trials are needed to confirm long-term efficacy, safety and optimal dosing strategies.